{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-25-000181","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.696476+00:00","generated_at":"2026-05-17T23:49:04.918846+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Chemed Q2 adjusted EPS $4.27 (-21.9% YoY); cuts FY2025 guidance; VITAS CEO departs","bullets":["GAAP EPS $3.57 (-23.2%); adjusted EPS $4.27 (-21.9%); revenue $618.8M (+3.8%).","VITAS adjusted EBITDA margin ex-Medicare cap 16.2% (-163 bps); Florida cap accrual $16.4M.","Roto-Rooter adjusted EBITDA margin 21.8% (-517 bps); revenue +0.6% to $222.6M.","FY2025 adjusted EPS guidance cut to $22.00-$22.30 from $24.95-$25.45; prior year $23.13.","VITAS CEO Nicholas Westfall resigns eff. July 29, 2025; Joel Wherley named successor."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-25-000181","json":"https://secwatch.observer/filing/0001562762-25-000181.json","markdown":"https://secwatch.observer/filing/0001562762-25-000181.md","text":"https://secwatch.observer/filing/0001562762-25-000181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276225000181/0001562762-25-000181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276225000181/che-20250729x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:49:04.918846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}